Abstract | BACKGROUND: METHODS: We conducted a comparative, open-label trial in 310 adults with AIDS who had recently recovered from an initial episode of PCP and had no treatment-limiting toxic effects of trimethoprim-sulfamethoxazole or pentamidine. All the patients were treated with zidovudine and were randomly assigned to receive either 800 mg of sulfamethoxazole and 160 mg of trimethoprim once daily or 300 mg of aerosolized pentamidine administered every four weeks by jet nebulizer. The participants were followed for a median of 17.4 months. RESULTS: CONCLUSIONS:
|
Authors | W D Hardy, J Feinberg, D M Finkelstein, M E Power, W He, C Kaczka, P T Frame, M Holmes, H Waskin, R J Fass |
Journal | The New England journal of medicine
(N Engl J Med)
Vol. 327
Issue 26
Pg. 1842-8
(Dec 24 1992)
ISSN: 0028-4793 [Print] United States |
PMID | 1448121
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Aerosols
- Zidovudine
- Pentamidine
- Trimethoprim, Sulfamethoxazole Drug Combination
|
Topics |
- AIDS-Related Opportunistic Infections
(prevention & control)
- Aerosols
- Female
- Follow-Up Studies
- Humans
- Male
- Pentamidine
(administration & dosage, toxicity)
- Pneumonia, Pneumocystis
(prevention & control)
- Random Allocation
- Recurrence
- Survival Rate
- Trimethoprim, Sulfamethoxazole Drug Combination
(administration & dosage, toxicity)
- Zidovudine
(therapeutic use)
|